Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
UBS
Accenture
Chubb
US Department of Justice
Daiichi Sankyo

Generated: March 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYCLOPENTOLATE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for CYCLOPENTOLATE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Summary
NCT00348166 Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children? Withdrawn KK Women's and Children's Hospital Phase 1 The purpose of this study is to find out if undercorrection of myopia slow down the progression of myopia in kindergarten children.
NCT01170130 Lidocaine Usage for Pupil Dilatation (Mydriasis) Completed Carmel Medical Center N/A The purpose of this study is to determine if the mydriatic effect of intracameral lidocaine 1% is as effective as topical cyclopentolate 1% and phenylephrine 10% for achieving effective mydriasis during phacoemulsification surgery.
NCT02177539 A New More Efficient Cycloplegia Scheme Unknown status Pontificia Universidad Catolica de Chile Phase 4 The purpose of this study is to determine whether tropicamide + phenylephrine cyclopentolate + applied for once waiting 30 minutes to retinoscopy (new scheme) is not inferior to apply cyclopentolate alone and wait 45 minutes to retinoscopy (traditional scheme)
NCT02309385 Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis Recruiting National Eye Institute (NEI) Phase 1/Phase 2 The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.
NCT02309385 Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis Recruiting Aciont Inc Phase 1/Phase 2 The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.
NCT02895035 Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size Not yet recruiting Milton S. Hershey Medical Center Phase 4 The objective of this study is to compare the maintenance of intraoperative mydriasis during cataract surgery between two drugs: epinephrine, which has routinely been used for decades, and Omidria, a newly FDA approved combination drug of phenylephrine and ketorolac. Patients undergoing cataract surgery that are enrolled in the trial will randomly receive one of the drugs in one eye, and the other eye will receive the drug during the subsequent cataract surgery.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for CYCLOPENTOLATE HYDROCHLORIDE

Condition Name

Condition Name for CYCLOPENTOLATE HYDROCHLORIDE
Intervention Trials
Cataract 2
Non-Infectious Anterior Uveitis 1
Myopia, Progressive 1
Refractive Errors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for CYCLOPENTOLATE HYDROCHLORIDE
Intervention Trials
Cataract 2
Refractive Errors 2
Myopia 2
Iridocyclitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for CYCLOPENTOLATE HYDROCHLORIDE

Trials by Country

Trials by Country for CYCLOPENTOLATE HYDROCHLORIDE
Location Trials
United States 5
Oman 1
Chile 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for CYCLOPENTOLATE HYDROCHLORIDE
Location Trials
Utah 1
Texas 1
North Dakota 1
North Carolina 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for CYCLOPENTOLATE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for CYCLOPENTOLATE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 2
Phase 1/Phase 2 1
Phase 1 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for CYCLOPENTOLATE HYDROCHLORIDE
Clinical Trial Phase Trials
Recruiting 2
Completed 1
Withdrawn 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for CYCLOPENTOLATE HYDROCHLORIDE

Sponsor Name

Sponsor Name for CYCLOPENTOLATE HYDROCHLORIDE
Sponsor Trials
Aciont Inc 1
National Eye Institute (NEI) 1
Pontificia Universidad Catolica de Chile 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for CYCLOPENTOLATE HYDROCHLORIDE
Sponsor Trials
Other 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Baxter
Julphar
Cipla
Daiichi Sankyo
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.